EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, KMDA:

29 Aug 2025
LAST:

6.920

CHANGE:
 0.10		OPEN:
7.010		HIGH:
7.040		ASK:
6.050		VOLUME:
24.5K
CHG(%):
1.42		PREV:
7.020		LOW:
6.904		BID:
3.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
29 Aug 257.0107.0406.9046.92024.5K
28 Aug 257.0207.1406.9707.02043.2K
27 Aug 256.9907.1406.9807.13032.1K
26 Aug 257.0307.0706.9707.05043.5K
25 Aug 257.1307.1857.0447.05029K
22 Aug 257.1107.2807.1107.18021.6K
21 Aug 256.9407.1006.9227.04528.3K
20 Aug 257.1907.1906.9206.97095.1K
19 Aug 257.2907.3407.1507.24035.1K
18 Aug 257.3107.3357.1707.17090.9K

COMPANY PROFILE

Name:
About:Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Sector:Healthcare
Address:2 Holzman Street, Rehovot, Israel, 7670402
Website:https://www.kamada.com
CUSIP:M6240T109
CIK:0001567529
ISIN:IL0010941198
FIGI:BBG004MPD1S4

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:22.63
DivYield:0.03
PtB:1.59
PtS:2.47
EBITDA:38.45M
Shares:57.51M
Market Cap:397.93M

TECHNICAL INDICATORS

MA5:7.03
MA10:7.08
MA20:7.14
MA50:7.46
MA100:7.10
MA200:6.88
RSI14:36.18
WPR14:-100.00
MTM14:-0.56
ROC14:-0.07
ATR:0.21
Week High:7.28
Week Low:6.90
Month High:7.85
Month Low:6.76
Year High:9.16
Year Low:5.17
Volatility:20.76

RECENT DIVIDENDS

Date Amount
17 Mar 2025$0.20
13 Jun 2013$0.01